Akums Drugs and Pharmaceuticals Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Akums reported a strong Q4, ending FY26 with a 5.8% revenue growth to INR4,359 Cr and a 13.3% rise in adjusted EBITDA to INR522 Cr (12% margin). PBT increased 11.9% to INR382 Cr.

The CDMO segment showed healthy growth, with management projecting double-digit volume expansion for H1 FY27. International CDMO is accelerating with EU GMP approval for Plant 2, targeting commercial supplies from FY28. The Zambia partnership anticipates ~INR230 Cr in supplies from India starting Q2 FY27.

API losses are expected to significantly reduce, while trade generics turned EBITDA positive. The company plans strategic investments in capacity expansion and M&A for continued growth.